Ovarian function during use of vaginal rings delivering three different doses of Nestorone.
Contraceptive vaginal rings delivering various progestins alone or in combination with estrogen have been previously studied, showing adequate steroid vaginal absorption and acceptability by the users. Nestorone progestin (NES) is a potent 19-nor-progesterone derivative, inactive by the oral route, but an excellent option for vaginal delivery. The purpose of this study was to evaluate ovarian function during 6 months of continuous use of progestin-only vaginal rings delivering 3 different doses of NES: 50, 75, and 100 microg per day. Blood samples were taken twice a week for 5 consecutive weeks during a control cycle and on months 1, 3 and 6 of use, for the measurement of estradiol (E2), progesterone (P), and NES. A total of 87 volunteers randomly received each of the 3 doses. After an initial peak, NES serum levels remained fairly constant throughout the duration of the study at about 125, 200 and 250 pmol/L, respectively, decreasing slightly with time. Luteal activity occurred very rarely (1.2-2.6% of sampling periods) with no apparent difference between doses. Low E2 levels (< or =100 pmol/L) in all samples of a run were rare (5%) and only with the high dose ring (100 microg/day). E2 remained within normal levels (101-1500 pmol/L) in most of the segments studied. We conclude that the 50 and 75 microg/day NES rings provide adequate ovulation inhibition without hypoestrogenism, while the 100 microg/day ring may deliver an unnecessarily high dose.
Brache
V
V
PROFAMILIA, Santo Domingo, Dominican Republic. biomedica@codetel.net.do
Mishell
D R
DR
Lahteenmaki
P
P
Alvarez
F
F
Elomaa
K
K
Jackanicz
T
T
Faundes
A
A
D000282:Administration, Intravaginal; D000293:Adolescent; D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000097:blood; D003274:Contraceptive Devices, Female; D004343:Drug Implants; D004958:Estradiol / Q000097:blood / Q000378:metabolism; D005260:Female; D006801:Humans; D009653:Norprogesterones / Q000008:administration & dosage* / Q000097:blood; D010053:Ovary / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D011374:Progesterone / Q000097:blood / Q000378:metabolism
D003271:Contraceptive Agents, Female; D004343:Drug Implants; D009653:Norprogesterones; D011374:Progesterone; D004958:Estradiol; C029167:ST 1435